QBIO News and Press, Q BioMed Inc From 05/30/19

NEW YORK , May 30, 2019 /PRNewswire/ --  5W Public Relations , one of the 15 largest independently-owned PR firms in the U.S., is pleased to announce it has been named PR Agency of Record for Q BioMed Inc. (OTCQB: QBIO),  a specialized pharmaceutical accelerator and co...

NEW YORK, NY / ACCESSWIRE / May 16, 2019 / WallstreetPR.com, the leading agency and financial media network dedicated to covering the biotech industry, announced the publication of an article covering Q BioMed Inc. (OTCQB: QBIO) and their innovative efforts to combat glaucoma- one of the l...

New York, New York--(Newsfile Corp. - April 24, 2019) - Q BioMed Inc . (OTCQB: QBIO), a biotechnology acceleration company, announced today its technology partner Mannin Research will be attending ARVO 2019 the Annual Meeting of the Association for Research in Vision and Ophthalmology from Ap...

NEW YORK, April 24, 2019 (GLOBE NEWSWIRE) -- Q BioMed Inc . (OTCQB: QBIO ), a biotechnology acceleration company, announced today its technology partner Mannin Research will be attending ARVO 2019 the Annual Meeting of the Association for Research in Vision and Ophthalmology from Apri...

April 10, 2019 Palm Beach, FL – April 10, 2019 – According to the Centers for Disease Control , autism affects an estimated 1 in 59 children in the United States today.  The Autism Speaks website defines the main problem for researchers/practitioners as: “We kn...

Marks the first time a company has identified biomarkers that hold the potential to stratify this subset of patients   Study examined 1,953 significant autistic biomarkers, resulting in 2 significant markers tied to expressed genes and pathways responsible for speech developmen...

New York, New York--(Newsfile Corp. - March 27, 2019) - "In the near-term, Q BioMed Inc. (OTCQB: QBIO) has multiple shots on goal with respect to market share, revenue and profit in the multi-billion dollar glaucoma market," says former Piper Jaffray analyst and mutual fund manager Rob Goldman...

NEW YORK, NY / ACCESSWIRE / March 21, 2019 / Q BioMed (OTCQB:QBIO) and its key technology partners are set to initiate development of an industry-changing diagnostic kit for monitoring glaucoma severity and progression. Pending FDA clearance, which could come sooner than many biotech investo...

Q BioMed ( OTCQB:QBIO ) and its key technology partners are set to initiate a diagnostic kit for monitoring glaucoma severity and progression. More news on: Q BioMed Inc., Healthcare stocks news, Read more ...

Q BioMed ( OTCQB:QBIO ) and its technology partner Mannin Research has entered into a research collaboration with the Biointerfaces Institute at McMaster University in Ontario, Canada to develop a GDF15 biomarker diagnostic kit for monitoring glaucoma severity and progression. More ...